Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Main subject
Language
Publication year range
1.
Clin Nutr ; 43(1): 84-94, 2024 01.
Article in English | MEDLINE | ID: mdl-38016243

ABSTRACT

BACKGROUND: Sarcopenia is associated with poor outcomes in patients with cirrhosis. However, the prevalence of and associated factors for developing sarcopenia in this population remain to be determined. OBJECTIVES: This study aimed to summarize the prevalence, characteristics, and associated factors of sarcopenia in patients with cirrhosis. METHODS: Electronic searches were performed from inception to June 9, 2022 to identify the eligible studies. We meta-analyzed the prevalence of sarcopenia in overall patients with cirrhosis and subgroups. Both crude and adjusted odds ratios (ORs) were pooled using the random effects model. RESULTS: A total of 55 studies involving 13,158 patients from 17 countries were included. The overall prevalence of sarcopenia was 40.1 % (95 % CI 35.4%-44.9 %) in patients with cirrhosis. The pooled prevalence was higher in males, Child-Pugh class C cirrhosis, decompensated stage, ascites, subjective global assessment class C cirrhosis, and when sarcopenia was defined by L3-SMI (third lumbar-skeletal muscle index) at a higher cutoff. In multivariate analysis, older age (adjusted OR 1.04, 95 % CI 1.00-1.07), male (adjusted OR 4.75, 95 % CI 2.72-8.28), lower body mass index (BMI) (adjusted OR 0.78, 95 % CI 0.73-0.83), alcoholic liver disease (ALD) (adjusted OR 1.43, 95 % CI 1.19-1.72), but not ascites and hepatic encephalopathy, were significantly associated with an increased risk of sarcopenia in patients with cirrhosis. CONCLUSION: Sarcopenia is a prevalent complication, and older age, male patients, lower BMI, and patients with ALD are associated with an increased risk of sarcopenia in patients with cirrhosis.


Subject(s)
Sarcopenia , Humans , Male , Sarcopenia/etiology , Sarcopenia/complications , Prevalence , Liver Cirrhosis/complications , Liver Cirrhosis/epidemiology , Muscle, Skeletal , Fibrosis , Ascites
2.
ACS Appl Mater Interfaces ; 10(34): 28664-28671, 2018 Aug 29.
Article in English | MEDLINE | ID: mdl-30079727

ABSTRACT

Recent progress in anion-exchange membranes has evoked increasing interests in alkaline polymer fuel cells (APFCs). A large body of recent research has demonstrated attractive activity of Fe-N macrocycle complexes as electrocatalysts for the oxygen reduction reaction (ORR) in alkaline media. To be a substitute for Pt in APFCs, however, most of the macrocycle molecules remain largely unsatisfactory in both of the catalytic activity and durability. Herein, we show that a one-pot microwave conjugation results in a polymerized iron-phthalocyanine (pFePc) which exhibits extremely high ORR performance, showing activity much better than that of the FePc monomer and 20 wt % Pt/C, and similar to that of the 60 wt % Pt/C under the same catalyst loading. Furthermore, we proposed an edge-closing strategy to significantly enhance the stability of the pFePc catalyst in alkaline media by eliminating the edge anhydride groups. Using the edge-closed pFePc as the cathode catalyst in APFC, a power density as high as 452 mW·cm-2 is achieved, which is among the best performance of non-noble metal catalyst-based APFCs so far reported.

SELECTION OF CITATIONS
SEARCH DETAIL
...